[
  {
    "ts": null,
    "headline": "Layoffs in 2024: A List of Companies Cutting Jobs This Year",
    "summary": "Google said it planned to lay off more employees this year but at a smaller scale than in 2023, when it cut more than 12,000 workers as part of large trims across the tech industry.  Chief Executive  Sundar Pichai  told employees in a Jan. 17 memo the company would have to make tough choices as it funded investments in areas like artificial intelligence.",
    "url": "https://finnhub.io/api/news?id=00ae9fef0806f577893746e912a579b9b59440a85c44c983455b3a84bccb7d3b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1706281800,
      "headline": "Layoffs in 2024: A List of Companies Cutting Jobs This Year",
      "id": 125324285,
      "image": "",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Google said it planned to lay off more employees this year but at a smaller scale than in 2023, when it cut more than 12,000 workers as part of large trims across the tech industry.  Chief Executive  Sundar Pichai  told employees in a Jan. 17 memo the company would have to make tough choices as it funded investments in areas like artificial intelligence.",
      "url": "https://finnhub.io/api/news?id=00ae9fef0806f577893746e912a579b9b59440a85c44c983455b3a84bccb7d3b"
    }
  },
  {
    "ts": null,
    "headline": "J&J eyes FDA approval for injection-based Tremfya in ulcerative colitis",
    "summary": "The request is based on findings from the Phase III ASTRO study, which achieved the primary endpoint of clinical remission at week 12.",
    "url": "https://finnhub.io/api/news?id=275bb01c5c38b6266999a0af2d4c67cc3be614a8589f9d1864c2c64396f2d4fa",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732296351,
      "headline": "J&J eyes FDA approval for injection-based Tremfya in ulcerative colitis",
      "id": 131567918,
      "image": "https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2024/11/shutterstock_1828134221-e1732291233689.jpg",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The request is based on findings from the Phase III ASTRO study, which achieved the primary endpoint of clinical remission at week 12.",
      "url": "https://finnhub.io/api/news?id=275bb01c5c38b6266999a0af2d4c67cc3be614a8589f9d1864c2c64396f2d4fa"
    }
  },
  {
    "ts": null,
    "headline": "Medtronic acquires Fortimedix Surgical to boost surgical portfolio",
    "summary": "Fortimedix Surgical’s portfolio consists of articulating instruments for endoscopic, robotic, and minimally invasive surgeries.",
    "url": "https://finnhub.io/api/news?id=3b341f8ff13fcbff7929bf59b27f4771c1231d3e79594b0dd6ef2b1a1823f49d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732295116,
      "headline": "Medtronic acquires Fortimedix Surgical to boost surgical portfolio",
      "id": 131569328,
      "image": "https://www.medicaldevice-network.com/wp-content/uploads/sites/23/2024/11/shutterstock_2083632559-1.jpg",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Fortimedix Surgical’s portfolio consists of articulating instruments for endoscopic, robotic, and minimally invasive surgeries.",
      "url": "https://finnhub.io/api/news?id=3b341f8ff13fcbff7929bf59b27f4771c1231d3e79594b0dd6ef2b1a1823f49d"
    }
  },
  {
    "ts": null,
    "headline": "Sanofi Plans to Change Hospital Drug-Discount Program",
    "summary": "The drugmaker looks to rein in how it gives discounts in a federal program designed to help hospitals that serve low-income and uninsured patients.",
    "url": "https://finnhub.io/api/news?id=6de1763df2f3393cce0cf4a3e829352d510a02110eb9378a12ba2a3b9e367e28",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732293540,
      "headline": "Sanofi Plans to Change Hospital Drug-Discount Program",
      "id": 131569331,
      "image": "https://media.zenfs.com/en/wsj.com/7b2c285183be07ca3c4e8242b25a59a8",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The drugmaker looks to rein in how it gives discounts in a federal program designed to help hospitals that serve low-income and uninsured patients.",
      "url": "https://finnhub.io/api/news?id=6de1763df2f3393cce0cf4a3e829352d510a02110eb9378a12ba2a3b9e367e28"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson stock underperforms Friday when compared to competitors",
    "summary": "Johnson & Johnson stock underperforms Friday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=fade9a8b3aef064706964fc38583add2822e5cb6714dd5d5f258798e226336e5",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732293060,
      "headline": "Johnson & Johnson stock underperforms Friday when compared to competitors",
      "id": 131598971,
      "image": "",
      "related": "JNJ",
      "source": "MarketWatch",
      "summary": "Johnson & Johnson stock underperforms Friday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=fade9a8b3aef064706964fc38583add2822e5cb6714dd5d5f258798e226336e5"
    }
  },
  {
    "ts": null,
    "headline": "Health Canada issues NOC to J&J’s CARVYKTI for multiple myeloma",
    "summary": "The study compared CARVYKTI's efficacy and safety against standard-of-care regimens in patients with multiple myeloma.",
    "url": "https://finnhub.io/api/news?id=f6f0ca74528dd913241f06030b769746e352dd23292841653d4c4058fddc60cb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732291685,
      "headline": "Health Canada issues NOC to J&J’s CARVYKTI for multiple myeloma",
      "id": 131567247,
      "image": "https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2024/11/Pharma-3-JJJ-Shutterstock_515341789.jpg",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The study compared CARVYKTI's efficacy and safety against standard-of-care regimens in patients with multiple myeloma.",
      "url": "https://finnhub.io/api/news?id=f6f0ca74528dd913241f06030b769746e352dd23292841653d4c4058fddc60cb"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie: Upgrading To 'Strong Buy' After Pullback",
    "summary": "AbbVieâs high dividend yield and leadership with Skyrizi and Rinvoq make it a top pick. Learn why ABBV stock is a strong buy for long-term growth.",
    "url": "https://finnhub.io/api/news?id=0df10e1bcbeba0158dcbfaf1a9f8e50e0b4cf1c080a74bf9c7b958beb9447381",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732288243,
      "headline": "AbbVie: Upgrading To 'Strong Buy' After Pullback",
      "id": 131571049,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2153992734/image_2153992734.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "AbbVieâs high dividend yield and leadership with Skyrizi and Rinvoq make it a top pick. Learn why ABBV stock is a strong buy for long-term growth.",
      "url": "https://finnhub.io/api/news?id=0df10e1bcbeba0158dcbfaf1a9f8e50e0b4cf1c080a74bf9c7b958beb9447381"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson seeks U.S. FDA approval for subcutaneous induction regimen of TREMFYA® (guselkumab) in ulcerative colitis, a first for an IL-23 inhibitor",
    "summary": "Johnson & Johnson (NYSE: JNJ) today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of a subcutaneous (SC) induction regimen of TREMFYA® (guselkumab) for the treatment of adults with moderately to severely active UC. The filing is supported by data from the Phase 3 ASTRO study of TREMFYA® SC induction therapy in adults with UC and builds upon the recent U.S. approval of TREMFYA® in this indication.",
    "url": "https://finnhub.io/api/news?id=a93ee218b12751b535bcc6f56bb451df8a0d7501d661eea29e8a1ccbf2e88147",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732280400,
      "headline": "Johnson & Johnson seeks U.S. FDA approval for subcutaneous induction regimen of TREMFYA® (guselkumab) in ulcerative colitis, a first for an IL-23 inhibitor",
      "id": 131567249,
      "image": "https://media.zenfs.com/en/prnewswire.com/388c9d27a537cc3a83771c29d6c3a86b",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE: JNJ) today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of a subcutaneous (SC) induction regimen of TREMFYA® (guselkumab) for the treatment of adults with moderately to severely active UC. The filing is supported by data from the Phase 3 ASTRO study of TREMFYA® SC induction therapy in adults with UC and builds upon the recent U.S. approval of TREMFYA® in this indication.",
      "url": "https://finnhub.io/api/news?id=a93ee218b12751b535bcc6f56bb451df8a0d7501d661eea29e8a1ccbf2e88147"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson (NYSE:JNJ) Stock Goes Ex-Dividend In Just Three Days",
    "summary": "Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Johnson...",
    "url": "https://finnhub.io/api/news?id=c79f03008b03efe2316e9de182365d9202e9e1c70150e83bee6b2f801ee28e1c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732277826,
      "headline": "Johnson & Johnson (NYSE:JNJ) Stock Goes Ex-Dividend In Just Three Days",
      "id": 131567250,
      "image": "https://media.zenfs.com/en/simply_wall_st__316/2eedc463aef15274c4887c130e30e298",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Johnson...",
      "url": "https://finnhub.io/api/news?id=c79f03008b03efe2316e9de182365d9202e9e1c70150e83bee6b2f801ee28e1c"
    }
  },
  {
    "ts": null,
    "headline": "J&J Sues HRSA Over Agency's Challenge Of Its Rebate Model",
    "summary": "On November 12, Johnson & Johnson filed suit against the Health Resources and Services Administration in D.C. federal district court, arguing that the 340B statute explicitly provides flexibility...",
    "url": "https://finnhub.io/api/news?id=c2339c574a28d92c2eaa69fc69a77b636cbce4bfe6ac0d91d18014b7ae790cca",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732273757,
      "headline": "J&J Sues HRSA Over Agency's Challenge Of Its Rebate Model",
      "id": 131566058,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "On November 12, Johnson & Johnson filed suit against the Health Resources and Services Administration in D.C. federal district court, arguing that the 340B statute explicitly provides flexibility...",
      "url": "https://finnhub.io/api/news?id=c2339c574a28d92c2eaa69fc69a77b636cbce4bfe6ac0d91d18014b7ae790cca"
    }
  },
  {
    "ts": null,
    "headline": "3 Dividend Kings So You Can Sleep Well At Night",
    "summary": "Discover why Dividend Kings like Coca-Cola, Johnson & Johnson, and Walmart are top long-term investments for their consistent growth and strong yields.",
    "url": "https://finnhub.io/api/news?id=8ff4be0507576b0b046216bc89c32f22ae776eb009c0a0a464792886a596e149",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732259700,
      "headline": "3 Dividend Kings So You Can Sleep Well At Night",
      "id": 131562113,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/155371886/image_155371886.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Discover why Dividend Kings like Coca-Cola, Johnson & Johnson, and Walmart are top long-term investments for their consistent growth and strong yields.",
      "url": "https://finnhub.io/api/news?id=8ff4be0507576b0b046216bc89c32f22ae776eb009c0a0a464792886a596e149"
    }
  },
  {
    "ts": null,
    "headline": "Lessons From Recent Decisions On Earnout Disputes",
    "summary": "Acquisition agreements sometimes include earnouts that provide for a portion of the purchase price to be payable only upon the achievement of specified milestones after the transaction closes. It is...",
    "url": "https://finnhub.io/api/news?id=a0bd205b0bb3e0e1b755769af9441ea122a15a33d48c28be168baa0fd00ab648",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732252207,
      "headline": "Lessons From Recent Decisions On Earnout Disputes",
      "id": 131559454,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "Acquisition agreements sometimes include earnouts that provide for a portion of the purchase price to be payable only upon the achievement of specified milestones after the transaction closes. It is...",
      "url": "https://finnhub.io/api/news?id=a0bd205b0bb3e0e1b755769af9441ea122a15a33d48c28be168baa0fd00ab648"
    }
  }
]